Austin, TX, USA · Temple, TX, USA
Biotechnology · DeepTech · Health
Summary: Advanced Scanners addresses a $20B market by implementing their unique technology to reduce errors in the navigation of surgeries on soft tissues, with an initial focus on reducing the catastrophic effects of brain-shift during brain surgery. An FDA Safety communication recently warned that errors in surgical navigation are "responsible for patient deaths, serious and life-threatening injuries, failed, aborted, and prolonged medical procedures." These errors affect millions of patients and cost U.S. hospitals billions in related costs each year. Advanced Scanners’ unique 3D vision platform aims to prevent the profound clinical and economic pains associated with these errors. With a robust product development pathway guided by a thorough regulatory analysis, we address a $20B market for surgical procedures and optical diagnosis of soft tissue. Beginning with neurosurgery, we have pilot-tested our radiation-free and contact-free device in a cadaver lab, successfully measured brain shift (the dominant error in brain surgery), and differentiated brain tissue based on certain optical properties. We are beginning an IRB-approved study (within the HCA system) on patients being treated via open craniotomy for brain cancer, stroke, and epilepsy. Our full-time team consists of the CTO, the inventor of our IP and a Ph.D. in Optical Sciences and Engineering; the CEO, a serial entrepreneur with multiple exits; a veteran sales engineer for multiple large imaging and neuronavigation companies; a software engineer with 20 years of highly relevant experience creating commercialized software that intraoperatively models soft tissue; a product development technician; and a Ph.D. brain researcher. We are engaged with a Fortune 50 medical device company to develop and integrate elements of our hardware and software solutions with their market-leading navigation system. We raised a $1.5M seed round earlier this year and expect to reach our milestones on schedule. At this time we are looking toward our next round of funding, a $4.5 million raise to reach our next set of milestones and initial exit opportunities.
Is this your company?
Something looks off?